BAY 3670549 / Bayer - LARVOL DELTA

FS.03: Topline Results in Heart Rhythm Care (AHA 2026) - "EU-CERT-ICD – Clinical Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators: Late Follow-Up Results of the EU-CERT-ICD Controlled Multi Center Cohort Study Rethinking Atrial Fibrillation (AF) Burden: AF Density Further Stratifies Heart Failure Risk in a Nationwide Cohort of Patients With Cardiac Devices Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF Subclinical AF and Stroke: Is There a Safe AF Burden? First-in-Human Evaluation of Bay 3670549, a Selective GIRK4 Inhibitor for Pharmacological Cardioversion in Patients With Atrial Fibrillation * LATENT – Artificial Intelligence-Guided Electrocardiographic Risk Stratification With Targeted Ambulatory Monitoring for Early Detection of Atrial Fibrillation and Pre-Atrial Fibrillation Atrial Findings: The LATENT Randomized Clinical Trial"

First-in-human • Late-breaking abstract • Atrial Fibrillation • Cardiovascular • Heart Failure

First-in-Human Evaluation of Bay 3670549, a Selective GIRK4 Inhibitor for Pharmacological Cardioversion in Patients With Atrial Fibrillation (AHA 2026) - No abstract available

Clinical • First-in-human • Late-breaking abstract • P1 data • Atrial Fibrillation • Cardiovascular

CARDIOVERT: A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Atrial Fibrillation • Cardiovascular

CARDIOVERT: A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation (clinicaltrials.gov) - P2 | N=360 | Not yet recruiting | Sponsor: Bayer

New P2 trial • Atrial Fibrillation • Cardiovascular

Bayer initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation (Bayer Press Release) - "The Phase II single-treatment study in a randomized, double-blind, placebo-controlled, parallel-group, multi-cohort design, will investigate the efficacy, safety and tolerability, as well as pharmacodynamics and pharmacokinetics of BAY 3670549 in adult patients with AFib."

Trial status • Atrial Fibrillation